Status:
COMPLETED
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
Lead Sponsor:
Erling Bjerregaard Pedersen
Conditions:
Nephropathy
Cardiovascular Diseases
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood. Nitric oxide...
Detailed Description
Subjects will be examined on two examination days. 4 days prior to each examination day subjects are treated with either atorvastatin or placebo. During treatment periods subject are given a standardi...
Eligibility Criteria
Inclusion
- Men and women
- minimum 40 years
- Chronic Kidney disease
- Estimated GFR (eGFR) between 30 and 90 ml/min
- Diabetes Mellitus type II
Exclusion
- Nephrotic Syndrome
- Anamnestic or clinical signs of significant heart, lung, lever, kidney and brain disease
- Neoplastic disease
- Alcohol abuse,
- Drug abuse
- Pregnancy or nursing
- Blood donation within a month before examination
- Hgb \< 6,0
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01208701
Start Date
May 1 2010
End Date
January 1 2012
Last Update
August 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medicinsk Forskning, Regionshospitalet Holstebro
Holstebro, Denmark, 7500